Evidence map›Paper›PMID 21364021›Full record

ArticleMolecular cancer research : MCR2011

HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance.

David L Schwartz, James Bankson, Luc Bidaut, Yi He, Ryan Williams, Robert Lemos, Arun Kumar Thitai, Junghwan Oh, Andrei Volgin, Suren Soghomonyan and 12 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Hypoxia-inducible factors as molecular targets for liver diseases.Journal of molecular medicine (Berlin, Germany) · 2016
    Review
  9. Article
  10. Article
  11. Review
  12. MR-based hypoxia measures in human glioma.Journal of neuro-oncology · 2013
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

David L SchwartzDepartment of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA. dschwartz3@nshs.edu
James Bankson
Luc Bidaut
Yi He
Ryan Williams
Robert Lemos
Arun Kumar Thitai
Junghwan Oh
Andrei Volgin
Suren Soghomonyan
Hsin-Hsien Yeh
Ryuichi Nishii
Uday Mukhopadhay
Mian Alauddin
Ioseb Mushkudiani
Norihito Kuno
Sunil Krishnan
William Bornman
Stephen Y Lai
Garth Powis
John Hazle
Juri Gelovani
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
SPORE in Gastrointestinal CancerP50CA095060 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 2002 to 2012
$25.3M
Therapeutic Targeting of Hypoxic and Oxidative StressP01CA017094 · NCI · UNIVERSITY OF ARIZONA · PI DORR, ROBERT T · 1985 to 2011
$13.7M
Hypoxia Inducible Factor and Anticancer Drug ActionR01CA098920 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI POWIS, GARTH · 2003 to 2013
$3.5M
Experimental Cancer Imaging Research Program (ECIRP)U24CA126577 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GELOVANI, JURI GEORGE, HAZLE, JOHN D. · 2007 to 2011
$2.2M
NCI NIH HHS CA017094NCI NIH HHS CA095060NCI NIH HHS CA098920NCI NIH HHS CA1019552NCI NIH HHS P01 CA017094NCI NIH HHS P30 CA016672NCI NIH HHS P30-CA016672NCI NIH HHS P50 CA095060NCI NIH HHS R01 CA098920NCI NIH HHS U24 CA126577NCI NIH HHS U24-CA126577
6 · The paper itself

Abstract

purposeHypoxia-inducible factor 1 (HIF-1) promotes cancer cell survival and tumor progression. The specific role played by HIF-1 and tumor-stromal interactions toward determining tumor resistance to radiation treatment remains undefined. We applied a multimodality preclinical imaging platform to mechanistically characterize tumor response to radiation, with a focus on HIF-1-dependent resistance pathways.

methodsC6 glioma and HN5 human squamous carcinoma cells were stably transfected with a dual HIF-1 signaling reporter construct (dxHRE-tk/eGFP-cmvRed2XPRT). Reporter cells were serially interrogated in vitro before and after irradiation as monolayer and multicellular spheroid cultures and as subcutaneous xenografts in nu/nu mice.

resultsIn vitro, single-dose irradiation of C6 and HN5 reporter cells modestly impacted HIF-1 signaling in normoxic monolayers and inhibited HIF-1 signaling in maturing spheroids. In contrast, irradiation of C6 or HN5 reporter xenografts with 8 Gy in vivo elicited marked upregulation of HIF-1 signaling and downstream proangiogenic signaling at 48 hours which preceded recovery of tumor growth. In situ ultrasound imaging and dynamic contrast-enhanced (DCE) MRI indicated that HIF-1 signaling followed acute disruption of stromal vascular function. High-resolution positron emission tomography and dual-contrast DCE-MRI of immobilized dorsal skin window tumors confirmed postradiotherapy HIF-1 signaling to spatiotemporally coincide with impaired stromal vascular function. Targeted disruption of HIF-1 signaling established this pathway to be a determinant of tumor radioresistance.

conclusionsOur results illustrate that tumor radioresistance is mediated by a capacity to compensate for stromal vascular disruption through HIF-1-dependent proangiogenic signaling and that clinically relevant vascular imaging techniques can spatially define mechanisms associated with tumor irradiation.

Indexed as

Adaptation, PhysiologicalAnimalsCell HypoxiaCell Line, TumorCell SurvivalHumansHypoxia-Inducible Factor 1IschemiaMiceMice, NudeNeoplasmsPositron-Emission TomographyRadiation ToleranceRatsSpheroids, CellularTransplantation, HeterologousHypoxia-Inducible Factor 1Vascular Endothelial Growth Factors

Identifiers

PMID21364021
PMCPMC3077053
OpenAlexW2109405796

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.